

Antifungal Drugs

Fungal CM disruption: nysta and ampho-B
 Ergosterol synthesis inhibition: Azoles and Allylamines
 Glucan synthesis inhibition: Echinocandins
 Nucleic Acid synthesis affectation: Flucytosine

Azole

Inhibition of synthesis of ergosterol:
 Inhibition of fungal CYP3A, Lanosterol 14 α demethylase

Imidazole

Triazole

Ketoconazole

Itraconazole

Fluconazole

Oral and topical; oral form are highly hepatotoxic; High pH decreases absorption thus cannot be combined with TIDINE and PRAZOLE family

Oral only; Highly bound to proteins; Metabolized to an active metabolite (hydroxyitraconazole; CYP3A4 inhibitor; increase absorption with food and low pH); less hepatotoxic but can cause stevens-johnson syndrome

High water soluble; oral and IV; high oral bioavailability; inhibitor of 3A4, 2C9 and 2C19

Sungal scalp inf.;
 Corticosteroid suppression; less sytemic use (orally)

CNS and Eye fungal infection

Allylamine

Terbinafine

Inhibits fungal squalene epoxidase through inhibition of aqualene monooxygenase enzyme; 99% bound to plasma protein; Accumulates in skin, nails and adipose tissue; metabolize in the liver and excreted through urine and feces

Dual effect of terbinafine: FUNGISTATIC due to ergosterol deficiency; FUNGICIDAL as an effect of squalene accumulation and ergosterol deficiency

ORALLY:
 Onychomycosis and Tinea capitis

Topical (cream/spray):
 dermatophytic infection cause by: Tinea corporis; Tinea cruris, tinea pedis; Cutaneous candidiasis; Tinea versicolor

Polyene antibiotic

Amphotericin B

An amphoteric polyene macrolide antibiotic derived from streptomyces; Binds to ergosterol causing leakage - cell death; water insoluble; Apho B + Na desoxycholate- IV infusion for systemic inf. (colloid form) and can also be use as topical; orally for upper GIT

90% bound to plasma protein (b-lipoprotein); 2-3% at CSF; excretion thru kidneys

Not absorbed from the GIT, skin and mucous membrane.

Disseminated inf. cause by aspergillus and candida; synergism with flucytosine increases its effect.
 ADVERSE EFFECT: Fever and chills (ABCD > C-AMB > ABLC > L-AMB); nephrotoxicity (C-AMB > ABLC > L-AMB > ABCD); Anemia; Hypokalemia; Hypomagnesemia; headache; tinnitus; nausea; vomiting

Formulation:

1. CONVENTIONAL AMPHOTERICIN B (C-AMB)- Lyophilized powder for injection; formed colloid mixture in D5 waer.

2. Liposomal Amphotericin B (L-AMB)- Small unilamellar formulation; Lyophilized powder + D5 water; Plasma concentration levels equivalent to C-AMB

3. Amphoterecin B Lipid Complex (ABLC)- Amphotericin B in LIPIDS; added to D%water; Lower plasma conc. than C-AMB

4. Amphotericin B Colloidal Dispersion (ABCD)- contains equimolar amounts of Ampho-B and cholesteryl sulfate for injection; Colloidal formation; much lower plasma conc. than C-AMB

Nystatin

Same mechanism with ApPOREtericin B. Too toxic for parenteral use;

Use mainly for local antifungal effect; For canida infection; Oropharyngeal thrush; Vaginal candidiasis; Intertrigenous candida infection.

echinocandins

Greseofulvin